All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The phase 1 dose escalation trial is designed to assess the dose, safety and tolerability of Radspherin® administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan,Rituximab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The study found that Betalutin (an anti-CD37 radioimmunoconjugate) acted synergistically with rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab-resistant xenograft NHL mouse model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UV1,GM-CSF,Pembrolizumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
The Phase I trial in malignant melanoma is evaluating the safety, tolerability and initial signs of clinical response in patients treated with UV1 in combination with pembrolizumab. Results confirm achievement of primary endpoints of safety and tolerability.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UV1,GM-CSF,Pembrolizumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2020
Details:
The study was designed to assess the safety and tolerability of UV1 combined with checkpoint inhibitor pembrolizumab and to explore initial signs of clinical response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): LTX-315
Therapeutic Area: Oncology Product Name: LTX-315
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Verrica Pharmaceuticals
Deal Size: $113.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2020
Details:
The licensing agreement is focused on developing and commercializing LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACT associated Chemotherapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 14, 2020
Details:
The net proceeds from the private placement will be used for: completion of phase I study of ACT® in liver metastases, initiate planning and conduct supporting studies for multi-indication oncology basket trial, further development of ACT®-therapy ultrasound probe.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ubidecarenone Coenzyme, Q-10
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
The study, presented at the 2020 American Society of Clinical Oncology Annual Meeting (ASCO), highlights safety, tolerability and the impact of BPM 31510-IV influence on metabolism in patients, supporting planned Phase 2 clinical development.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ONCOS-102,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma who have had disease progression on treatment with anti-PD1 CPI.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
